Attorneys Representing Type 2 Diabetics Who Diagnosed With Heart Failure While Taking Onglyza or Kombiglyze XR
The U.S. Food and Drug Administration (FDA) is investigating potential increased heart failure risks linked to Onglyza and Kombiglyze XR. A recent study by the New England Journal of Medicine prompted the FDA to look further into the side effects of Onglyza and Kombiglyze XR.
FDA Advisory Committee Suggests Warning Label or Withdrawal From The Market
The FDA assembled a panel to examine the link between Onglyza and heart failure in type 2 diabetics in light of the new information found by the study done by the New England Journal of Medicine. Of the 15 Endocrinologic and Metabolic Drugs Advisory Committee members, 14 recommended a label update and one recommended the product be removed from the market altogether. The label update suggested by the panel is to warn patients about the potential for increased risk of heart failure when taking Onglyza.
While Onglyza and Kombiglyze XR did pass the FDA’s initial requirements of not showing significant increased risk of heart problems, the recent panel’s findings caused enough concern to get the FDA to consider an updated warning. Panelists determined that patients taking Onglyza faced a 27% increased risk of being hospitalized for heart failure.
Discuss Your Legal Rights With an Onglyza Side Effects Attorney
Our pharmaceutical litigation attorneys are offering a Free Consultation to anyone who was diagnosed with heart failure while taking Onglyza or Kombiglyze XR. There are time constraints to file Onglyza lawsuits, so get your Free Case Evaluation to get started right away.